Are We Considering All the Potential Drug-Drug Interactions in Women's Reproductive Health? A Predictive Model...

Area of Science:

• Pharmacology
• Reproductive Medicine
• Computational Biology

Background:

• Drug-drug interactions (DDIs) can cause adverse effects or synergistic outcomes, with most combinations unassessed in clinical trials.
• Predicting DDIs aids patient management, prevents negative drug combinations, and identifies synergistic therapies, particularly in women's healthcare.

Purpose of the Study:

• To develop and validate a predictive model for drug-drug interactions (DDIs) relevant to reproductive treatments.
• To identify novel DDIs between reproductive drugs and commonly used medications, assessing their potential clinical impact.

Main Methods:

• Utilized drug features including chemical structure, side effects, targets, and pathways to build a DDI prediction model.
• Employed a unified predictive score to identify unknown DDIs and their clinical effects on reproductive health.
• Validated model performance using known drug-drug interactions, achieving high accuracy (AUROC = 0.9876).

Main Results:

• Identified 2991 novel DDIs among 192 drugs used in female reproductive conditions and other medications.
• Highlighted significant interactions involving estradiol, acetaminophen, bupivacaine, risperidone, and follitropin, with high discovery rates for follitropin, bupivacaine, and gonadorelin.
• Predicted 23 beneficial DDIs, 11 harmful interactions, and 12 potential DDIs between oral contraceptives and HIV drugs that may affect efficacy.

Conclusions:

• DDI prediction is vital for identifying interactions that could compromise or enhance therapeutic efficacy in women's reproductive health.
• Findings support the personalization of female reproductive therapies through a better understanding of drug-drug interactions.